Premier Anti-Aging Co., Ltd.

As of January 31, 2025, Premier Anti-Aging Co., Ltd. carries a market capitalization of 7.01B, placing it among publicly traded companies globally. Its enterprise value stands at 3.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Premier Anti-Aging Co., Ltd.'s next confirmed earnings release is scheduled for December 11, 2026.

As of January 31, 2025, Premier Anti-Aging Co., Ltd. has 8.72M shares outstanding.

These figures are as of January 31, 2025.

As of January 31, 2025, Premier Anti-Aging Co., Ltd. maintains a current ratio of 2.67, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended January 31, 2025.

Over the twelve months ended January 31, 2025, Premier Anti-Aging Co., Ltd. recorded 572.00M in income tax expense.

As of the close on October 22, 2026, Premier Anti-Aging Co., Ltd.'s stock has declined approximately 20.64% over the past 52 weeks. The 50-day moving average sits at 590.52, while the 200-day moving average is 635.87.

As of January 31, 2025, Premier Anti-Aging Co., Ltd. holds 5.31B in cash and equivalents against 1.78B in total debt, resulting in a net debt position of -3.53B. Total book value stands at 6.71B, with working capital of 5.55B providing operational flexibility.